


Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-Nov-2020
Document Type: USP Monographs
DocId: GUID-B4D16448-3C0C-46EA-A174-5C81E31DA438_4_en-US
DOI: https://doi.org/10.31003/USPNF_M49795_04_01
DOI Ref: wqv4c

© 2025 USPC
Do not distribute

Metformin Hydrochloride



$C_4H_{11}N_5 \cdot HCl$ 165.62

Imidodicarbonimidic diamide, *N,N*-dimethyl-, monohydrochloride;

1,1-Dimethylbiguanide monohydrochloride CAS RN®: 1115-70-4; UNII: 786Z46389E.

DEFINITION

Change to read:

Metformin Hydrochloride contains ▲NLT 98.0% and NMT 102.0%▲ (USP 1-May-2020) of metformin hydrochloride ($C_4H_{11}N_5 \cdot HCl$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- ▲A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K or 197A▲ (USP 1-May-2020)
- ▲B. [IDENTIFICATION TESTS—GENERAL \(191\), Chemical Identification Tests, Chloride](#): Meets the requirements

Add the following:

- ▲C. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.▲ (USP 1-May-2020)

ASSAY

Change to read:

• PROCEDURE

▲**Buffer:** 9.8 g/L of [monobasic ammonium phosphate](#) in [water](#)

Mobile phase: [Buffer](#) and [acetonitrile](#) (95:5). Adjust with [phosphoric acid](#) to a pH of 3.0.

Standard solution: 0.05 mg/mL of [USP Metformin Hydrochloride RS](#) in *Mobile phase*. Sonication may be used to promote dissolution. Allow the solution to equilibrate to ambient temperature.

Sample solution: 0.05 mg/mL of Metformin Hydrochloride in *Mobile phase*. Sonication may be used to promote dissolution. Allow the solution to equilibrate to ambient temperature.

[NOTE—Silanized HPLC vials may be used.]

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 25-cm; 10-μm packing [L9](#)

Flow rate: 1.5 mL/min

Injection volume: 20 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2

Relative standard deviation: NMT 0.73%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of metformin hydrochloride ($C_4H_{11}N_5 \cdot HCl$) in the portion of Metformin Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of metformin from the *Sample solution* r_S = peak response of metformin from the *Standard solution* C_S = concentration of [USP Metformin Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Metformin Hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the dried basis▲ (USP 1-May-2020)**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- **ORGANIC IMPURITIES**

Mobile phase: 17 g/L of [monobasic ammonium phosphate](#) in [water](#); adjusted with [phosphoric acid](#) to a pH of 3.0**System suitability stock solution:** 0.25 mg/mL of ▲[USP Metformin Hydrochloride RS](#)▲ (USP 1-May-2020) and 0.1 mg/mL of ▲[USP Melamine RS](#)▲ (USP 1-May-2020) in [water](#)**System suitability solution:** ▲5 µg/mL of [USP Metformin Hydrochloride RS](#) and 2 µg/mL of [USP Melamine RS](#) from *System suitability stock solution* in *Mobile phase*▲ (USP 1-May-2020)**Standard stock solution:** 0.2 mg/mL of [USP Metformin Related Compound A RS](#) in [water](#)**Standard solution:** 0.001 mg/mL of [USP Metformin Related Compound A RS](#) from *Standard stock solution* in *Mobile phase***Sample solution:** 5 mg/mL of Metformin Hydrochloride in *Mobile phase***Diluted sample solution:** 0.005 mg/mL of Metformin Hydrochloride in *Mobile phase* from the *Sample solution***Chromatographic system**(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 218 nm**Column:** 4.6-mm × 25-cm; packing L9**Flow rate:** 1.0–1.7 mL/min**Injection volume:** 20 µL**Run time:** NLT 2 times the retention time of metformin**System suitability****Sample:** *System suitability solution***Suitability requirements****Resolution:** NLT 10 between melamine and metformin**Analysis****Samples:** *Standard solution*, *Sample solution*, and *Diluted sample solution*

Calculate the percentage of metformin related compound A in the portion of Metformin Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of metformin related compound A from the *Sample solution* r_S = peak response of metformin related compound A from the *Standard solution* C_S = concentration of [USP Metformin Related Compound A RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Metformin Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of any other impurity in the portion of Metformin Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times D \times 100$$

 r_U = peak response of any individual impurity from the *Sample solution* r_S = peak response of metformin from the *Diluted sample solution* D = dilution factor for the preparation of the *Diluted sample solution*, 0.001**Acceptance criteria****Individual impurities:** NMT 0.02% for metformin related compound A; NMT 0.1% for any other impurity**Total impurities:** NMT 0.5%**SPECIFIC TESTS**

- [Loss on Drying \(731\)](#).

Analysis: Dry at 105° for 5 h.

Acceptance criteria: NMT 0.5%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at room temperature.

Change to read:

- [USP REFERENCE STANDARDS \(11\)](#)

▲ [USP Melamine RS](#)

2,4,6-Triamino-1,3,5-triazine.

$C_3H_6N_6$ 126.12▲ (USP 1-May-2020)

[USP Metformin Hydrochloride RS](#)

[USP Metformin Related Compound A RS](#)

1-Cyanoguanidine.

$C_2H_4N_4$ 84.08

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METFORMIN HYDROCHLORIDE	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 44(6)

Current DocID: [GUID-B4D16448-3C0C-46EA-A174-5C81E31DA438_4_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M49795_04_01

DOI ref: [wqv4c](#)